Zacks Research Has Optimistic Outlook of NTLA Q3 Earnings

Key Points

• Zacks Research has improved its earnings per share (EPS) forecast for Intellia Therapeutics, now expecting a loss of ($1.16) for Q3 2025, up from a prior estimate of ($1.19).
• The company reported EPS of ($0.99) for the last quarter, surpassing analyst expectations by $0.04, with a notable revenue increase of 104.3% year-over-year.
• Multiple analysts have recently adjusted their price targets for Intellia Therapeutics, with most rating the stock as a Buy, indicating a consensus average price target of $29.05.

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Analysts at Zacks Research boosted their Q3 2025 earnings per share (EPS) estimates for shares of Intellia Therapeutics in a research note issued to investors on Monday, September 8th. Zacks Research analyst Team now forecasts that the company will post earnings per share of ($1.16) for the quarter, up from their previous forecast of ($1.19). The consensus estimate for Intellia Therapeutics' current full-year earnings is ($5.07) per share. Zacks Research also issued estimates for Intellia Therapeutics' Q4 2025 earnings at ($1.25) EPS, FY2025 earnings at ($4.50) EPS, Q1 2026 earnings at ($1.19) EPS, Q2 2026 earnings at ($1.21) EPS, Q3 2026 earnings at ($1.07) EPS, Q4 2026 earnings at ($1.12) EPS, FY2026 earnings at ($4.59) EPS, Q1 2027 earnings at ($0.89) EPS, Q2 2027 earnings at ($1.04) EPS and FY2027 earnings at ($4.21) EPS.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.99) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The business had revenue of $14.25 million during the quarter, compared to the consensus estimate of $12.26 million. During the same quarter last year, the company earned ($1.52) EPS. Intellia Therapeutics's revenue was up 104.3% on a year-over-year basis.

Several other brokerages also recently issued reports on NTLA. Wedbush reiterated a "neutral" rating and issued a $7.00 price objective on shares of Intellia Therapeutics in a research report on Monday, June 16th. HC Wainwright cut their price objective on Intellia Therapeutics from $30.00 to $25.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Wall Street Zen upgraded Intellia Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, September 6th. Canaccord Genuity Group cut their price objective on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating for the company in a research report on Tuesday, June 3rd. Finally, Chardan Capital cut their price objective on Intellia Therapeutics from $68.00 to $60.00 and set a "buy" rating for the company in a research report on Monday, August 11th. Eleven investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $27.11.

Intellia Therapeutics Price Performance

NTLA remained flat at $11.42 during trading on Wednesday. The company's stock had a trading volume of 3,334,902 shares, compared to its average volume of 3,896,501. The company's 50 day moving average price is $11.62 and its 200 day moving average price is $9.61. Intellia Therapeutics has a 52-week low of $5.90 and a 52-week high of $23.76. The company has a market capitalization of $1.23 billion, a PE ratio of -2.43 and a beta of 2.28.

Institutional Investors Weigh In On Intellia Therapeutics

Institutional investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Intellia Therapeutics during the fourth quarter worth $25,000. Headlands Technologies LLC bought a new stake in shares of Intellia Therapeutics in the second quarter valued at about $26,000. Whipplewood Advisors LLC lifted its holdings in shares of Intellia Therapeutics by 114,900.0% in the second quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company's stock valued at $32,000 after purchasing an additional 3,447 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in Intellia Therapeutics by 56.4% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company's stock worth $33,000 after acquiring an additional 1,655 shares in the last quarter. Finally, Harbour Investments Inc. raised its holdings in Intellia Therapeutics by 76.7% during the first quarter. Harbour Investments Inc. now owns 5,214 shares of the company's stock worth $37,000 after acquiring an additional 2,264 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Intellia Therapeutics

In related news, Director William J. Chase acquired 100,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 20th. The stock was acquired at an average cost of $10.03 per share, with a total value of $1,003,000.00. Following the completion of the purchase, the director directly owned 134,693 shares in the company, valued at approximately $1,350,970.79. This trade represents a 288.24% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Edward J. Dulac III sold 7,462 shares of Intellia Therapeutics stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total value of $104,617.24. Following the sale, the executive vice president directly owned 106,062 shares of the company's stock, valued at approximately $1,486,989.24. This trade represents a 6.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,534 shares of company stock valued at $153,837 over the last three months. Insiders own 3.10% of the company's stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.